Cargando…
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
BACKGROUND: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with...
Autores principales: | Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Hubalek, Michael, Petru, Edgar, Sandholzer, Margit, Andel, Johannes, Balic, Marija, Melchardt, Thomas, Hauser-Kronberger, Cornelia, Schmitt, Clemens A., Ulmer, Hanno, Greil, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529308/ https://www.ncbi.nlm.nih.gov/pubmed/34691243 http://dx.doi.org/10.1177/17588359211042301 |
Ejemplares similares
-
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
por: Gampenrieder, Simon Peter, et al.
Publicado: (2021) -
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018) -
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021) -
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022) -
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)